Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study-Reference-Cited by-同舟云学术

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

Published:2016-02-11 Issue:2 Volume:17 Page:63-71
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Poizot-Martin Isabelle,Bellissant Eric,Garraffo Rodolphe,Colson Philippe,Piroth Lionel,Solas Caroline,Renault Alain,Bourlière Marc,Halfon Philippe,Ghosn Jade,Alric Laurent,Naqvi Alissa,Carrieri Patrizia,Molina Jean-Michel,

Funder

French National Agency for Research on AIDS and Viral Hepatitis(ANRS)

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1080/15284336.2015.1135553

Reference15 articles.

1. Hepatitis C, from screening to treatment, a revolution

2. Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir

3. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors

4. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

5. The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database;British Journal of Clinical Pharmacology;2021-10-13

2. Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases;Antiviral Research;2017-05

3. Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy;AIDS;2016-08-24

4. ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study);Antiviral therapy;2016